Cargando…
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis
BACKGROUND: Treatment with fingolimod for multiple sclerosis (MS) reduces the efficacy of COVID-19 vaccination. The aim of this exploratory study was to evaluate whether main lymphocyte subsets and demographic features correlated to the subsequent increase in anti-SARS-CoV2 antibodies following the...
Autores principales: | Schiavetti, Irene, Barcellini, Lucrezia, Lapucci, Caterina, Tazza, Francesco, Cellerino, Maria, Capello, Elisabetta, Franciotta, Diego, Inglese, Matilde, Sormani, Maria Pia, Uccelli, Antonio, Laroni, Alice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800324/ https://www.ncbi.nlm.nih.gov/pubmed/36603292 http://dx.doi.org/10.1016/j.msard.2022.104494 |
Ejemplares similares
-
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021) -
Different MRI patterns in MS worsening after stopping fingolimod
por: Lapucci, Caterina, et al.
Publicado: (2019) -
Tailoring B cell depletion therapy in MS according to memory B cell monitoring
por: Novi, Giovanni, et al.
Publicado: (2020) -
In-vivo characterization of macro- and microstructural injury of the subventricular zone in relapsing-remitting and progressive multiple sclerosis
por: Cellerino, Maria, et al.
Publicado: (2023) -
Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
por: Tazza, F., et al.
Publicado: (2021)